Florbetaben PET Imaging in PPA

The University of Chicago

Status: Completed

Conditions: Primary Progressive Aphasia; Alzheimer Disease

Treatments: Drug: Florbetaben F18; Device: PET

Study type: Observational

Funder types: Other

Identifiers

NCT04720001

IRB23-1360

Details and patient eligibility

About

The purpose of this research is to better understand how dementia affects activity in different parts of the brain.

Full description

This study will examine Positron Emission Tomography (PET) imaging with Florbetaben F18. Florbetaben F18 is a radioactive tracer that binds to particles in your brain. This process displays activity in the brain. Florbetaben F18 is a PET amyloid imaging agent approved by the United States Food and Drug Administration (FDA) to estimate the amount of beta-amyloid plaque in adult patients who are being evaluated for Alzheimer's disease and other causes of cognitive decline. The purpose of this research is to better understand how dementia affects activity in different parts of the brain. Currently, the scientific community is limited by how well it can see inside the brain. The use of a PET scan better helps us understand what the brain looks like in a diseased state. Participation in the study will help to understand what brain activity looks like, especially around language regions.

Enrollment: 1 patient

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants must have a diagnosis of PPA or a related dementia syndrome

Exclusion criteria

• Pregnant
• Breastfeeding
• Receiving radiation clinically

Trial design

1 participants in 1 patient group

Experimental: Florbetaben F18 recipients

Description:

Participants in this arm of the study will receive 8.1mCi of florbetaben F18 and then be scanned in a PET scanner for brain imaging.

Treatment:

Device: PET

Drug: Florbetaben F18